🧾 What This Document Is

This is an 8-K filing from SCYNEXIS, a biotech company. Attached is the main event: a Securities Purchase Agreement. Think of it as a formal IOU and rulebook for a major cash deal. The company is selling stock and warrants to a group of investors to raise money. This document spells out the exact terms, promises both sides make, and what happens next.

🏢 What The Company Does

In simple terms… SCYNEXIS is a pharmaceutical company focused on developing new drugs, particularly novel antifungal treatments to fight serious infections. They are clinical-stage, meaning their products are still being tested and are not yet generating significant revenue from sales.

💰 Financial Highlights of the Deal

• Raising Capital: The company is selling a combination of common stock and two types of warrants to investors.
• Price Per Unit:
  • One share of common stock + one Common Warrant is sold for $0.92.
  • One Pre-Funded Warrant + one Common Warrant is sold for $0.9199.
• Warrant Exercise Prices:
  • Pre-Funded Warrants: Can be exercised almost for free at $0.0001 per share. These are used by investors who want shares immediately but need to manage ownership thresholds.
  • Common Warrants: Can be exercised at $1.20 per share. This gives investors the right to buy more stock later at a set price.
• Who's Selling: SCYNEXIS, Inc.
• Who's Buying: A group of institutional investors listed in a separate exhibit.
• Placement Agent: Guggenheim Securities, LLC helped arrange the deal.

🚀 Key Moves & Deal Mechanics

• The Closing: The money and securities will be exchanged within five business days of the agreement (dated March 30, 2026).
• Stockholder Approval Needed: The company doesn't have enough authorized shares to cover all the potential warrants. They promise to get shareholder approval to increase the authorized share count, a common step in these deals.
• Registration Rights: Investors get the right to demand the company register their new shares with the SEC for public resale. This helps them eventually sell their investment.
• "Blacked Out" from New Sales: For about 60 days after closing, the company cannot issue new stock or file new registration statements, with some exceptions like employee plans. This protects the investors from immediate dilution.

📦 What This Signals for Financial Position

This deal will significantly boost SCYNEXIS's cash position. For a clinical-stage biotech, cash is oxygen—it funds expensive research, clinical trials, and operations until a drug is approved and can be sold. However, it also dilutes existing shareholders. The new shares and potential shares from warrants mean each existing share represents a smaller piece of the company.

🔮 What's Next

1. Immediate: The deal will close, and cash will hit the company's bank account.
2. Soon After: The company will file a registration statement to allow investors to resell their shares.
3. Strategic: Management will use this capital to advance its clinical programs and fund the business. The next major milestone will be seeking stockholder approval to authorize more shares.
4. Investor Action: The warrant holders will decide if and when to exercise their warrants at $1.20, which would bring more cash into the company.

⚖️ Big Picture: Strengths & Risks

👍 Strengths / Why This is Good:

• Fuels the Pipeline: Provides critical funding to advance drug development without taking on debt.
• Strong Backing: Raises capital from sophisticated institutional investors, a sign of confidence.
• Clean Terms: The deal structure with Pre-Funded Warrants is common and efficient for large investors.

⚠️ Risks / What to Watch:

• Shareholder Dilution: This is the biggest near-term impact. More shares outstanding will reduce earnings per share.
• Execution Risk: The money must be used effectively to achieve clinical milestones. No guarantee of success.
• Market Reaction: Investors often react negatively to dilutive offerings in the short term, which can pressure the stock price.

🧠 The Analogy

Imagine SCYNEXIS is a high-potential startup building a revolutionary new engine (a breakthrough drug). They've run out of their own money to finish it. Instead of taking a bank loan (debt), they sell pieces of their future company (stock and warrants) to a group of wealthy venture capitalists (the investors). This gives them the cash to finish the engine, but the original founders now own a smaller slice of the finished pie. The investors are betting the finished engine will be so valuable that their smaller slice will be worth much more than what they paid.

📇 Key Contacts & People

• Placement Agent: Guggenheim Securities, LLC (Noted as the financial advisor for the deal)
• Transfer Agent: Equiniti Trust Company, LLC (The firm that manages the company's stock records)

🧩 Final Takeaway

SCYNEXIS is raising vital cash for its drug development through a classic biotech financing deal. While this strengthens its balance sheet and funds future research, it comes at the cost of diluting current shareholders. The deal's success now hinges on the company using this capital to achieve key clinical milestones that increase its long-term value.